Answer
Juluca’s dolutegravir binds to the HIV integrase active site and blocks the strand-transfer step of viral DNA integration essential for replication, while rilpivirine non-competitively inhibits HIV-1 reverse transcriptase.
Sources for this answer
- Juluca 50 mg/25 mg film-coated tabletsViiV Healthcare UK Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 19Document updated
Sources checked